TP53 status and gene amplification in human colorectal carcinomas

Cancer Genetics and Cytogenetics

Volumn 115, Issue 2, 1999, Pages 118-122

  Soulié, Priscilla ^a   Fourme, Emmanuelle ^b   Hamelin, Richard ^d   Asselain, Bernard ^b   Salmon, Rémy Jacques ^c   Dutrillaux, Bernard ^a   Muleris, Martine ^a  

^a CNRS   (France)

^b HÔpital Bichat   (France)

^c Department of Surgery ^*  (France)

^d INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADULT; AGED; ARTICLE; CARCINOGENESIS; COLORECTAL CARCINOMA; CYTOGENETICS; DENATURING GRADIENT GEL ELECTROPHORESIS; FEMALE; GENE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL;

AGED; COLORECTAL NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENE REARRANGEMENT; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM STAGING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032756823     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(99)00073-4     Document Type: Article

References (34)

1. Wright J.A., Smith H.S., Watt F.M., Hancock M.C., Hudson D.L., Stark G.R. DNA amplification is rare in normal cells. Proc Natl Acad Sci USA. 87:1990;1791-1795.
2. Tlsty T.D. Normal diploid human and rodent cells lack a detectable frequency of gene amplification. Proc Natl Acad Sci USA. 87:1990;3132-3136.
3. Toledo F., Buttin G., Debatisse M. The origin of chromosome rearrangements at early stages of AMPD2 gene amplification in Chinese hamster cells. Curr Biol. 3:1993;255-264.
4. Stark G.R. Regulation and mechanisms of mammalian gene amplification. Adv Cancer Res. 61:1993;87-113.
5. Ma C., Martin S., Trask B., Hamlin J.L. Sister chromatid infusion initiates amplification of the dihydrofolate reductase gene in Chinese hamster cells. Genes Dev. 7:1993;605-620.
6. Toledo F., LeRescouet D., Buttin G., Debatisse M. Co-amplified markers alternate in megabase long chromosomal inverted repeats and cluster independently in interphase nuclei at early steps of mammalian gene amplification. EMBO J. 11:1992;2665-2673.
7. Windle B.E., Draper B.W., Yin Y., O'Gorman S., Wahl G.M. A central role for chromosome breakage in gene amplification, deletion formation, and amplicon integration. Genes Dev. 5:1991;160-174.
8. Livingston L.R., White A., Sprouse J., Livanos E., Jacks T., Tlsty T.D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell. 70:1992;923-935.
9. Perry M.E., Commane M., Stark G.R. Simian virus large tumor antigen alone or two cooperating oncogenes convert REF52 cells to a state permissive for gene amplification. Proc Natl Acad Sci USA. 89:1992;8112-8116.
10. Schaefer D.I., Livanos E.M., White A.E., Tlsty T.D. Multiple mechanisms of N-(phosphonoacetyl)-L-aspartate drug resistance in SV40-infected precrisis human fibroblasts. Cancer Res. 53:1993;4946-4951.
11. Yin Y., Tainsky M.A., Bischoff F.Z., Strong L.C., Wahl G.M. Wild type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell. 70:1992;937-948.
12. Dulic V., Kaufmann W.K., Wilson S.J., Tlsty T.D., Lees M., Harper W., Elledge S.J., Reed S.I. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell. 76:1994;1013-1023.
13. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
14. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 cdk-interacting protein cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:1993;805-816.
15. Nelson W.G., Kastan M.B. DNA strand breaks. the DNA template alterations that trigger p53-dependent DNA damage response pathways Mol Cell Biol. 14:1994;1815-1823.
16. Seshadri R., Leong A.S., McCaul K., Firgaira F.A., Seltur V., Horsfall D.J. Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis. Int J Cancer. 69:1996;135-141.
17. Eyfjörd J.E., Thorlacius S., Steinarsdottir M., Valgardsdottir R., Ögmundsdottir H.M., Anamthawat-Jonsson K. p53 abnormalities and genomic instability in primary human breast carcinomas. Cancer Res. 55:1995;646-651.
18. Lang F.F., Miller D.C., Koslow M., Newcomb E.W. Pathways leading to glioblastoma multiforme. a molecular analysis of genetic alterations in 65 astrocytic tumors J Neurosurg. 81:1994;427-436.
19. Rasheed B.K.A., McLendon R.E., Herndon J.E., Friedman H.S., Friedman A.H., Bigner D.D., Bigner S.H. Alterations of the TP53 gene in human gliomas. Cancer Res. 54:1994;1324-1330.
20. Habuchi T., Kinoshita H., Yamada H., Kakehi Y., Ogawa O., Wu W.-J., Takahashi R., Sugiyama T., Yoshida O. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. J Natl Cancer Inst. 86:1994;1331-1335.
21. Muleris M., Salmon R.J., Dutrillaux B. Cytogenetics of colorectal adenocarcinomas. Cancer Genet Cytogenet. 49:1990;143-156.
22. Mitelman F. Catalog of Chromosome Aberrations in Cancer. 1994;Wiley-Liss, New York.
23. Soussi T., Legros Y., Lubin R., Ory K., Schlichtholz B. Multifactorial analysis of p53 alteration in human cancer. a review Int J Cancer. 57:1994;1-9.
24. Hamelin R., Jego N., Laurent-Puig P., Vidaud M., Thomas G. Efficient screening of p53 mutations by denaturing gel electrophoresis in colorectal tumors. Oncogene. 8:1993;2213-2220.
25. Hoang J.M., Cottu P.H., Thuille B., Salmon R.J., Thomas G., Hamelin R. BAT-26 an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res. 57:1997;300-303.
26. Zhou X.P., Hoang J.M., Li Y.J., Seruca R., Carneiro F., Sobrinho-Simoes M., Lothe R.A., Gleeson C.M., Russel S.E.H., Muzeau F., Flejou J.F., Hoang-Xuan K., Lidereau R., Thomas G., Hamelin R. Determination of the replication error phenotype in human tumors without requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosom Cancer. 21:1998;101-107.
27. Remvikos Y., Tominaga O., Hammel P., Laurent-Puig P., Salmon R.J., Dutrillaux B., Thomas G. Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer. 66:1992;758-764.
28. Hamelin R., Laurent-Puig P., Olschwang S., Jego N., Asselain B., Remvikos Y., Girodet J., Salmon R.J., Thomas G. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology. 107:1994;1571-1572.
29. Scott N., Sagar P., Stewart J., Blair G.E., Dixon M.F., Quirke P. p53 in colorectal cancer. clinicopathological correlation and prognosis significance Br J Cancer. 63:1991;317-319.
30. Ionov Y., Peinado M.A., Malkosyan S., Shibata D., Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for cologenic carcinogenesis. Nature. 363:1993;558-561.
31. Remvikos Y., Muleris M., Salmon R.J., Dutrillaux B. The different routes to colorectal carcinoma. implications for the search of key genetic events Cancer Genet Cytogenet. 99:1997;63-73.
32. Niederacher D., Schnurch H.G., An H.X., Ellenberger I., Dall P., VanRoeyen C.R., Kuppers V., Beckmann M.W. Detection of sequential genetic alterations relevant for breast cancer development. Eur J Cancer Prev. 5:1996;497-503.
33. Cottu P.H., Muzeau F., Estreicher A., Flejou J.F., Iggo R., Thomas G., Hamelin R. Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines. Oncogene. 13:1996;2727-2730.
34. Olschwang S., Hamelin R., Laurent-Puig P., Thuille B., DeRycke Y., Li Y.-J., Muzeau F., Girodet J., Salmon R.-J., Thomas G. Alternative genetic pathways in colorectal carcinogenesis. Proc Natl Acad Sci USA. 94:1997;12122-12127.